Oncolytics Biotech (ONCY) director adds 25,000 shares in open-market buy

Rhea-AI Filing Summary

Oncolytics Biotech Inc. director Deborah Margaret Brown bought additional company shares. On February 12, 2026, she made an open-market purchase of 25,000 common shares at a weighted average price of $0.8496 per share. After this transaction, she directly owns 109,851 common shares of Oncolytics Biotech Inc.

The filing notes that the purchase price reflects multiple trades executed within a range from $0.835 to $0.85 per share, and detailed trade breakdowns are available upon request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Deborah Margaret

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/12/2026		P		25,000	A	$0.8496(1)	109,851	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.835 to $0.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

	/s/ Kirk Look, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Oncolytics Biotech (ONCY) disclose in this filing?

Oncolytics Biotech disclosed that director Deborah Margaret Brown bought 25,000 common shares in an open-market transaction. The purchase occurred on February 12, 2026, and reflects her increasing direct ownership stake in the company’s common shares.

At what price did the Oncolytics Biotech (ONCY) director buy shares?

Director Deborah Margaret Brown purchased the 25,000 common shares at a weighted average price of $0.8496 per share. The filing explains that the trades were executed in multiple transactions within a price range of $0.835 to $0.85.

How many Oncolytics Biotech (ONCY) shares does the director own after this transaction?

Following the reported purchase, director Deborah Margaret Brown directly owns 109,851 common shares of Oncolytics Biotech. This total reflects her holdings immediately after the February 12, 2026 open-market acquisition of 25,000 additional shares reported in the filing.

What type of transaction was reported for Oncolytics Biotech (ONCY) director Deborah Brown?

The transaction reported is an open-market purchase of common shares by director Deborah Margaret Brown. It is coded as a purchase transaction, indicating she increased her direct ownership through buys executed on February 12, 2026 at market prices.

Does the Oncolytics Biotech (ONCY) Form 4 mention a price range for the director’s share purchases?

Yes. The filing notes that the $0.8496 price is a weighted average, with shares bought in multiple trades between $0.835 and $0.85. The director offers to provide detailed trade-by-trade pricing information to the issuer, security holders, or SEC staff upon request.